
Levicept presents Phase II data showing LEVI-04 may modify osteoarthritis disease and improve symptoms.
Levicept Ltd revealed Phase II clinical trial data for LEVI-04, a novel osteoarthritis treatment, at the EULAR 2026 conference. The data suggest LEVI-04 not only relieves pain but may also modify the disease by reducing bone marrow lesions linked to ...

